Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes
Authors' conclusion
Antidiabetic medication-associated, and specifically GLP-1RA-associated, weight loss and HbA1c reductions independently reduce real-world clinical outcome risk.
Study context
- Population
- Patients with T2D evaluated at the Cleveland Clinic, 1 January 2000–31 December 2020
- Participants
- 8,876 vs 4,161
- Exposure
- Body mass index (BMI) and HbA1c reduction during antidiabetic drug treatment, including GLP-1 RA
- Cohort An = 8,876
- Cohort Bn = 4,161
- Outcome
- Association of BMI and HbA1c reduction with clinical outcomes
Methodological detailsobservational, electronic health record-derived data
- Observational
- Electronic health record-derived data
Main finding
As reported in the abstract
- Cohort A: each 1% BMI reduction, reduced risk of HF (p = 0.017)
- 3%
- Cohort A: each 1% BMI reduction, reduced risk of insulin initiation (p = 0.001)
- 4%
- Cohort A: each 1% (≈11 mmol/mol) HbA1c reduction, reduced risk of hypertension (p = 0.041)
- 4%
- Cohort A: each 1% (≈11 mmol/mol) HbA1c reduction, reduced risk of insulin initiation (p = 0.001)
- 29%
- Cohort B: each 1% BMI reduction, reduced risk of CVD (p = 0.008)
- 4%
- Cohort B: each 1% BMI reduction, reduced risk of insulin initiation (p = 0.002)
- 3%
- Cohort B: each 1% (≈11 mmol/mol) HbA1c reduction, reduced risk of CKD (p = 0.014)
- 4%
- Cohort B: each 1% (≈11 mmol/mol) HbA1c reduction, reduced risk of insulin initiation (p = 1 × 10-4)
- 16%
Observational data: associations, not effects.
Further findings
- Lower BMI variability and greater BMI durability associated with decreased risk of clinical outcomes in both cohorts
Original publication
Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes. Diabetes Obes Metab. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →